Key result
Co-delivery of doxorubicin and curcumin using a polypeptide nanocarrier (L-DOX + CUR) synergistically increased cytotoxicity and apoptosis in lymphoma cells and suppressed tumor growth in xenograft mice with reduced toxicity.
Why the study?
Doxorubicin has nonselective adverse effects limiting its clinical combinations, and delivery optimization combined with curcumin could enhance synergistic efficacy in invasive B cell lymphoma.
Population
Invasive B cell lymphoma cell lines, Kunming mice, and tumor-bearing SCID mice
Comparison
L-DOX + CUR vs DOX alone or L-DOX alone
Design
Preclinical in vitro and in vivo animal study
Authors
Loading...
Hypothesis-generating for nanocarrier co-delivery in lymphoma; leaves open clinical translation.
p-value: p=<0.001
Co-delivery of doxorubicin and curcumin via a novel polypeptide nanocarrier synergistically enhances cytotoxicity against B-cell lymphoma and reduces in vivo toxicity.
Guo et al. (2020) studied Invasive B cell lymphoma. L-DOX + CUR (polypeptide nanocarrier co-loaded with Doxorubicin and Curcumin) vs. DOX alone, L-DOX, DOX + CUR, CUR alone, or PBS was evaluated on Tumor volume growth and apoptosis rate (p=<0.001). Co-delivery of doxorubicin and curcumin using a polypeptide nanocarrier (L-DOX + CUR) synergistically increased cytotoxicity and apoptosis in lymphoma cells and suppressed tumor growth in xenograft mice with reduced toxicity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: